Expand SMMT Menu
SMMT MENU

SMMT Latest Press Releases

-- September 22, 2026 --

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026 Business Wire 6:00 AM

-- September 15, 2026 --

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients Business Wire 6:00 AM

-- September 13, 2026 --

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China Business Wire 7:00 AM

-- September 2, 2026 --

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China Business Wire 5:41 PM

-- August 25, 2026 --

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China Business Wire 6:00 PM
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology Business Wire 7:00 AM

-- August 12, 2026 --

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer Business Wire 9:22 AM

-- August 6, 2026 --

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty Globe Newswire 4:07 PM

-- August 5, 2026 --

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer Business Wire 7:00 AM

-- July 27, 2026 --

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm PRNewswire 8:52 AM

-- July 23, 2026 --

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 Business Wire 4:05 PM

-- July 22, 2026 --

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer Business Wire 4:30 PM
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer Business Wire 4:30 PM
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study Business Wire 6:30 AM

-- July 17, 2026 --

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm Globe Newswire 4:01 PM

-- July 16, 2026 --

Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 Business Wire 8:00 AM

-- July 14, 2026 --

Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. Business Wire 7:00 AM

-- June 25, 2026 --

The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution Globe Newswire 11:39 AM

-- June 9, 2026 --

Summit Therapeutics Announces Proposed Public Offering of Common Stock Business Wire 4:47 PM

-- June 4, 2026 --

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference Business Wire 4:30 PM

-- May 31, 2026 --

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Business Wire 9:06 AM

-- May 30, 2026 --

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 Business Wire 8:00 AM

-- May 14, 2026 --

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology Globe Newswire 9:15 AM

-- May 4, 2026 --

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 9:23 AM

-- April 30, 2026 --

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 Business Wire 4:32 PM
Market Data Delayed 15 Minutes